Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis
Status:
Completed
Trial end date:
2019-08-16
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the
efficacy and safety of E6007 once daily for 8 weeks in Japanese participants with moderate
active ulcerative colitis. Participants will be stratified by prior therapeutic treatment and
Mayo score at Baseline, and will be randomized 1:1:1 to receive E6007 30 milligrams (mg),
E6007 60 mg or placebo.